Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic DermatitisGlobeNewsWire • 05/28/24
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic DermatitisBusiness Wire • 05/28/24
Cancer victims file class action against Johnson & Johnson over ‘fraudulent' bankruptciesNew York Post • 05/24/24
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc LitigationBusiness Wire • 05/22/24
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Johnson & Johnson StockThe Motley Fool • 05/21/24
Johnson & Johnson (JNJ) Up 5.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 05/16/24
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis TreatmentBusiness Wire • 05/16/24